Subscribe To
VECT / VectivBio Holding AG (VECT) CEO Luca Santarelli on Q4 2021 Results - Earnings Call Transcript
VECT News
By The Motley Fool
May 22, 2023
Why Shares of VectivBio Holding Are Up Today
Ironwood Pharmaceuticals' buyout deal is worth $1 billion. The attraction was VectivBio's late-stage therapy, apraglutide. more_horizontal
By Investors Business Daily
May 22, 2023
VectivBio Stock Catapults 38% After Ironwood Agrees To Buy It For $1 Billion
Ironwood Pharmaceuticals said Monday it will buy VectivBio for $1 billion. The deal sent VECT stock flying, while IRWD stock skidded. more_horizontal
By Barrons
May 22, 2023
Ironwood Pharmaceuticals to Acquire VectivBio for About $1 Billion
Ironwood Pharmaceuticals is paying $17 a share for the Swiss biotech company. more_horizontal
By Market Watch
May 22, 2023
Ironwood Pharmaceuticals to acquire Swiss biotech VectivBio in deal valued at about $1 billion
Ironwood Pharmaceuticals Inc. IRWD, +2.45% said Monday it has agreed to acquire Swiss biotech VectivBio Holding AG VECT, +8.18% for $17 a share in cas more_horizontal
By Seeking Alpha
April 17, 2023
VectivBio: Swiss Company With Excellent Data, Upcoming Catalysts
VectivBio: Swiss Company With Excellent Data, Upcoming Catalysts more_horizontal
By GlobeNewsWire
November 9, 2022
VectivBio to Present at the 2022 Jefferies London Healthcare Conference
BASEL, Switzerland, Nov. 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical compan more_horizontal
By Seeking Alpha
April 7, 2022
VectivBio Holding AG (VECT) CEO Luca Santarelli on Q4 2021 Results - Earnings Call Transcript
VectivBio Holding AG (VECT) CEO Luca Santarelli on Q4 2021 Results - Earnings Call Transcript more_horizontal
By GlobeNewsWire
February 8, 2022
VectivBio to Present at the SVB Leerink 11th Annual Global Healthcare Conference
BASEL, Switzerland, Feb. 08, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical compan more_horizontal